184 related articles for article (PubMed ID: 38611036)
1. Utility Scores for Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy: Mapping to EQ-5D.
Oxley SG; Wei X; Sideris M; Blyuss O; Kalra A; Sia JJY; Ganesan S; Fierheller CT; Sun L; Sadique Z; Jin H; Manchanda R; Legood R
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611036
[TBL] [Abstract][Full Text] [Related]
2. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
[TBL] [Abstract][Full Text] [Related]
5. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
Choi YH; Terry MB; Daly MB; MacInnis RJ; Hopper JL; Colonna S; Buys SS; Andrulis IL; John EM; Kurian AW; Briollais L
JAMA Oncol; 2021 Apr; 7(4):585-592. PubMed ID: 33630024
[TBL] [Abstract][Full Text] [Related]
6. Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis.
Wei X; Oxley S; Sideris M; Kalra A; Brentnall A; Sun L; Yang L; Legood R; Manchanda R
Am J Obstet Gynecol; 2023 Oct; 229(4):388-409.e4. PubMed ID: 37059410
[TBL] [Abstract][Full Text] [Related]
7. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J
Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420
[TBL] [Abstract][Full Text] [Related]
8. Attitudes toward Risk-Reducing Mastectomy and Risk-Reducing Salpingo-oophorectomy among Young, Unmarried, Healthy Women in Korea.
Park B; Kim D; Kim J; Lee BY; Yoon J; Kim SW
Cancer Res Treat; 2022 Apr; 54(2):375-382. PubMed ID: 34384016
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of risk-reducing surgery in unaffected women at increased familial risk of breast and/or ovarian cancer.
Heiniger L; Butow PN; Coll J; Bullen T; Wilson J; Baylock B; Meiser B; Price MA
Fam Cancer; 2015 Mar; 14(1):105-15. PubMed ID: 25283514
[TBL] [Abstract][Full Text] [Related]
10. Uptake and efficacy of bilateral risk reducing surgery in unaffected female
Marcinkute R; Woodward ER; Gandhi A; Howell S; Crosbie EJ; Wissely J; Harvey J; Highton L; Murphy J; Holland C; Edmondson R; Clayton R; Barr L; Harkness EF; Howell A; Lalloo F; Evans DG
J Med Genet; 2022 Feb; 59(2):133-140. PubMed ID: 33568438
[TBL] [Abstract][Full Text] [Related]
11. Estimating the disutility of relapse in relapsing-remitting and secondary progressive multiple sclerosis using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-psychosocial, and SF-6D: implications for health economic evaluation models.
Ahmad H; Campbell JA; van der Mei I; Taylor BV; Xia Q; Zhao T; Palmer AJ
Qual Life Res; 2023 Dec; 32(12):3373-3387. PubMed ID: 37522942
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian Cancer Prevention: A Systematic Review.
Wei X; Oxley S; Sideris M; Kalra A; Sun L; Yang L; Legood R; Manchanda R
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551605
[TBL] [Abstract][Full Text] [Related]
13. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
[TBL] [Abstract][Full Text] [Related]
14. Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer.
Ladd MK; Peshkin BN; Senter L; Baldinger S; Isaacs C; Segal H; Philip S; Phillips C; Shane K; Martin A; Weinstein V; Pilarski R; Jeter J; Sweet K; Hatten B; Wurtmann EJ; Phippen S; Bro D; Schwartz MD
Transl Behav Med; 2020 May; 10(2):337-346. PubMed ID: 30418620
[TBL] [Abstract][Full Text] [Related]
15. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
Chai X; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Tung N; Weitzel JN; Couch FJ; Hulick PJ; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Blum JL; Domchek SM; Chen J; Rebbeck TR
Breast Cancer Res Treat; 2014 Nov; 148(2):397-406. PubMed ID: 25311111
[TBL] [Abstract][Full Text] [Related]
16. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
[TBL] [Abstract][Full Text] [Related]
17. Urinary incontinence more than 15 years after premenopausal risk-reducing salpingo-oophorectomy: a multicentre cross-sectional study.
Terra L; Heemskerk-Gerritsen BAM; Beekman MJ; Engelhardt E; Mourits MJE; van Doorn HC; de Hullu JA; Mom CH; Slangen BFM; Gaarenstroom KN; van Beurden M; Roeters Van Lennep JE; van Dorst EBL; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; Steensma AB; van Leeuwen FE
BJOG; 2024 Jan; 131(1):99-108. PubMed ID: 37394722
[TBL] [Abstract][Full Text] [Related]
18. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.
McCrone P; Patel A; Knapp M; Schene A; Koeter M; Amaddeo F; Ruggeri M; Giessler A; Puschner B; Thornicroft G
J Ment Health Policy Econ; 2009 Mar; 12(1):27-31. PubMed ID: 19346564
[TBL] [Abstract][Full Text] [Related]
19. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis.
Manchanda R; Legood R; Antoniou AC; Gordeev VS; Menon U
J Med Genet; 2016 Sep; 53(9):591-9. PubMed ID: 27354448
[TBL] [Abstract][Full Text] [Related]
20. Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations.
Julian-Reynier C; Mancini J; Mouret-Fourme E; Gauthier-Villars M; Bonadona V; Berthet P; Fricker JP; Caron O; Luporsi E; Noguès C
Eur J Hum Genet; 2011 May; 19(5):500-6. PubMed ID: 21267012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
